Abstract: Sanitization edge compute devices are discussed herein. For example, an ozone generator may be controlled to output ozone in an environment to achieve a first ozone concentration level at a first time. A first decay rate of the ozone in the environment may be determined from the first ozone concentration level during a first period of time. The ozone generator may be controlled to output the ozone in the environment to a second ozone concentration level at a second time. A second decay rate of the ozone in the environment may be determined from the second ozone concentration level during a second period of time. A difference between the first decay rate and the second decay rate may be determined. An action may be performed based on the difference.

Abstract: Reporting and alerting for ozone based sanitization are discussed herein. For example, the ozone decay data indicating a decay rate of ozone in an environment may be received. The ozone decay data may be collected by a first computing device configured to control an ozone generator in the environment. A decay signature may be determined based at least in part on the ozone decay data. Information associated with a sanitization state associated with the environment may be determined based on the decay signature. A graphical user interface (GUI) may be provided to a second computing device. The GUI may include information indicative of the sanitization state.

Abstract: Sanitization central computing devices are discussed herein. For example, log data may be received from a computing device configured to control an ozone generator. The log data may be indicative of a parameter and ozone decay rate data associated with an environment. The log data may be input to a machine learned model. A control parameter may be received from the machine learned model. The control parameter may be associated with operating the computing device to disinfect the environment. The control parameters may be sent to the computing device to control the ozone generator.

Abstract: Sanitization systems with safety features are discussed herein. For example, one or more cleaning devices arranged in an environment can be controlled to generate ozone and/or emit UVC light in the environment. One or more motion sensors associated with the environment may detect a motion. Upon determining that the motion is detected by the one or more motion sensors, the one or more cleaning devices can be controlled to stop generating ozone and emitting the UVC light in the environment.

Abstract: A smart-structure that includes a securable occupiable space, access to which is controlled by a controller and a personal mobile computing device of a prospective occupant desiring to occupy the securable occupiable space. In some embodiments, access to the personal occupiable space is controlled by an electronic access-control lock that a prospective occupant can cause to unlock via personal area network (PAN) communications directly between a personal mobile computing device and the controller of the smart-structure. Once within the securable occupiable space, the controller may use an occupancy signal to provide the occupant with temporary control of one or more controllable environmental systems associated with the securable occupiable space. Other interactions between a prospective occupant/occupant, former occupant and the smart-structure are also disclosed.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

Abstract: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.

Abstract: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.